Alonso-Lana S., Marquié M., Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020;12:588872. https://doi.org/10.3389/fnagi.2020.588872..
DOI: 10.3389/fnagi.2020.588872

World Health Organization (2020). Coronavirus Disease (COVID-19) Situation Report-190. Available at: https://who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6.https://who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6

World Health Organization (2020). Coronavirus Disease (COVID-19) Situation Report-190. Available at: https://who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6.https://who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6

Boutoleau-Bretonnière C., Pouclet-Courtemanche H., Gillet A., Bernard A., Deruet A.L., Gouraud I. et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer’s Disease During the COVID-19 Crisis. J Alzheimers Dis. 2020;76(1):41–47. https://doi.org/10.3233/JAD-200604..
DOI: 10.3233/JAD-200604

Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648..
DOI: 10.1001/jama.2020.2648

Tsai S.T., Lu M.K., San S., Tsai C.H. The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review. Front Neurol. 2020;11:498. https://doi.org/10.3389/fneur.2020.00498..
DOI: 10.3389/fneur.2020.00498

Lim S., Bae J.H., Kwon H.S., Nauck M.A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4..
DOI: 10.1038/s41574-020-00435-4

Cariou B., Hadjadj S., Wargny M., Pichelin M., Al-Salameh A., Allix I. et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–1515. https://doi.org/10.1007/s00125-020-05180-x..
DOI: 10.1007/s00125-020-05180-x

Pitocco D., Viti L., Santoliquido A., Tartaglione L., Di Leo M., Bianchi A. et al. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetol. 2021;58(5):669–670. https://doi.org/10.1007/s00592-020-01658-7..
DOI: 10.1007/s00592-020-01658-7

Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P. et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. https://doi.org/10.2337/dc10-1303..
DOI: 10.2337/dc10-1303

Odriozola A., Ortega L., Martinez L., Odriozola S., Torrens A., Corroleu D. et al. Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection. Diabetes Res Clin Pract. 2021;172:108631. https://doi.org/10.1016/j.diabres.2020.108631..
DOI: 10.1016/j.diabres.2020.108631

Kioskli K., Scott W., Winkley K., Kylakos S., McCracken L.M. Psychosocial factors in painful diabetic neuropathy: a systematic review of treatment trials and survey studies. Pain Med. 2019;20:1756–1773. https://doi.org/10.1093/pm/pnz071..
DOI: 10.1093/pm/pnz071

Yang H., Sloan G., Ye Y., Wang S., Duan B., Tesfaye S., Gao L. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2020;10:929. https://doi.org/10.3389/fendo.2019.00929..
DOI: 10.3389/fendo.2019.00929

Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962. https://doi.org/10.2337/diacare.28.4.956..
DOI: 10.2337/diacare.28.4.956

Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):CD007543. https://doi.org/10.1002/14651858.CD007543.pub2..
DOI: 10.1002/14651858.CD007543.pub2

Ang L., Jaiswal M., Martin C., Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. https://doi.org/10.1007/s11892-014-0528-7..
DOI: 10.1007/s11892-014-0528-7

1Cullen W., Gulati G., Kelly B.D. Mental health in the COVID-19 pandemic. QJM. 2020;113(5):311–312. https://doi.org/10.1093/qjmed/hcaa110..
DOI: 10.1093/qjmed/hcaa110

Pérez-Cano H.J., Moreno-Murguía M.B., Morales-López O., Crow-Buchanan O., English J.A., Lozano-Alcázar J., Somilleda-Ventura S.A. Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic. Cir Cir. 2020;88(5):562–568. https://doi.org/10.24875/CIRU.20000561..
DOI: 10.24875/CIRU.20000561

Smarr K.L., Keefer A.L. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 2011;63(11 Suppl.):S454–466. https://doi.org/10.1002/acr.20556..
DOI: 10.1002/acr.20556

Richter P., Werner J., Heerlein A., Kraus A., Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998;31(3):160–168. https://doi.org/10.1159/000066239..
DOI: 10.1159/000066239

Beck S.B. Еyelid conditioning as a function of cs intensity, ucs intensity, and manifest anxiety scale score. J Exp Psychol. 1963;66:429–438. https://doi.org/10.1037/h0042820..
DOI: 10.1037/h0042820

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. https://doi.org/10.1136/jnnp.23.1.56..
DOI: 10.1136/jnnp.23.1.56

Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601. https://doi.org/10.1093/occmed/kqv054..
DOI: 10.1093/occmed/kqv054

Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393–400. https://doi.org/10.1111/j.1526-4637.2008.00555.x..
DOI: 10.1111/j.1526-4637.2008.00555.x

Centre for Clinical Practice at NICE (UK). Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings. London: National Institute for Health and Care Excellence, (UK); 2013. Available at: https://pubmed.ncbi.nlm.nih.gov/25577930..
DOI: 10.1111/j.1526-4637.2008.00555.xhttps://pubmed.ncbi.nlm.nih.gov/25577930

Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–496. https://doi.org/10.1007/s40263-014-0164-4..
DOI: 10.1007/s40263-014-0164-4https://pubmed.ncbi.nlm.nih.gov/25577930

Tesfaye S., Vileikyte L., Rayman G., Sindrup S.H., Perkins B.A., Baconja M. et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638. https://doi.org/10.1002/dmrr.1225..
DOI: 10.1002/dmrr.1225

Tesfaye S., Vileikyte L., Rayman G., Sindrup S.H., Perkins B.A., Baconja M. et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638. https://doi.org/10.1002/dmrr.1225..
DOI: 10.1007/s40263-014-0164-4

Lunn M.P., Hughes R.A., Wiffen P.J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014:Cd007115. https://doi.org/10.1002/14651858.CD007115.pub3..
DOI: 10.1002/14651858.CD007115.pub3

Lunn M.P., Hughes R.A., Wiffen P.J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014:Cd007115. https://doi.org/10.1002/14651858.CD007115.pub3..
DOI: 10.1002/dmrr.1225

Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121. https://doi.org/10.1111/j.1464-5491.2004.01109.x..
DOI: 10.1111/j.1464-5491.2004.01109.x

Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121. https://doi.org/10.1111/j.1464-5491.2004.01109.x..
DOI: 10.1002/14651858.CD007115.pub3

Строков И.А., Фокина А.С., Строков К.И., Дроконова О.О. Современные принципы диагностики и лечения диабетической полинейропатии. Медицинский совет. 2014;(5):38–43. https://doi.org/10.21518/2079-701X-2014-5-38-43..
DOI: 10.21518/2079-701X-2014-5-38-43

Строков И.А., Фокина А.С., Строков К.И., Дроконова О.О. Современные принципы диагностики и лечения диабетической полинейропатии. Медицинский совет. 2014;(5):38–43. https://doi.org/10.21518/2079-701X-2014-5-38-43..
DOI: 10.1111/j.1464-5491.2004.01109.x

Cure E., Cumhur Cure M. Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection. Med Hypotheses. 2020;143:110185. https://doi.org/10.1016/j.mehy.2020.110185..
DOI: 10.1016/j.mehy.2020.110185

Cure E., Cumhur Cure M. Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection. Med Hypotheses. 2020;143:110185. https://doi.org/10.1016/j.mehy.2020.110185..
DOI: 10.21518/2079-701X-2014-5-38-43

Zhong M., Sun A., Xiao T., Yao G., Sang L., Zheng X. et al. A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20066266..
DOI: 10.1101/2020.04.15.20066266

Zhong M., Sun A., Xiao T., Yao G., Sang L., Zheng X. et al. A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20066266..
DOI: 10.1016/j.mehy.2020.110185

Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425–1433. https://doi.org/10.1007/BF00400603..
DOI: 10.1007/BF00400603

Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425–1433. https://doi.org/10.1007/BF00400603..
DOI: 10.1101/2020.04.15.20066266

Ziegler D., Reljanovic M., Mehnert H., Gries F.A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107(7):421–430. https://doi.org/10.1055/s-0029-1212132..
DOI: 10.1055/s-0029-1212132

Ziegler D., Reljanovic M., Mehnert H., Gries F.A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107(7):421–430. https://doi.org/10.1055/s-0029-1212132..
DOI: 10.1007/BF00400603

Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776. https://doi.org/10.2337/diacare.26.3.770..
DOI: 10.2337/diacare.26.3.770

Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776. https://doi.org/10.2337/diacare.26.3.770..
DOI: 10.1055/s-0029-1212132

Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9(3):294–299. https://doi.org/10.1038/nm834..
DOI: 10.1038/nm834

Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9(3):294–299. https://doi.org/10.1038/nm834..
DOI: 10.2337/diacare.26.3.770

Ang C.D., Alviar M.J., Dans A.L., Bautista-Velez G.G., Villaruz-Sulit M.V., Tan J.J. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;(3):CD004573. https://doi.org/10.1002/14651858.CD004573.pub3..
DOI: 10.1002/14651858.CD004573.pub3

Ang C.D., Alviar M.J., Dans A.L., Bautista-Velez G.G., Villaruz-Sulit M.V., Tan J.J. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;(3):CD004573. https://doi.org/10.1002/14651858.CD004573.pub3..
DOI: 10.1038/nm834

Луцкий И.С., Лютикова Л.В., Луцкий Е.И. Витамины группы В в неврологической практике. Международный неврологический журнал. 2008;(5):89–93. Режим доступа: https://www.mif-ua.com/archive/article/7441..
DOI: 10.1002/14651858.CD004573.pub3https://www.mif-ua.com/archive/article/7441

Bâ A. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol. 2008;28(7):923–931. https://doi.org/10.1007/s10571-008-9297-7..
DOI: 10.1007/s10571-008-9297-7https://www.mif-ua.com/archive/article/7441

Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 2005;43(2):71–77. https://doi.org/10.5414/cpp43071..
DOI: 10.5414/cpp43071

Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 2005;43(2):71–77. https://doi.org/10.5414/cpp43071..
DOI: 10.1007/s10571-008-9297-7

Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. https://doi.org/10.1055/s-2008-1065351..
DOI: 10.1055/s-2008-1065351

Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. https://doi.org/10.1055/s-2008-1065351..
DOI: 10.5414/cpp43071

Mooney S., Leuendorf J.E., Hendrickson C., Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules. 2009;14(1):329–351. https://doi.org/10.3390/molecules14010329..
DOI: 10.3390/molecules14010329

Mooney S., Leuendorf J.E., Hendrickson C., Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules. 2009;14(1):329–351. https://doi.org/10.3390/molecules14010329..
DOI: 10.1055/s-2008-1065351

Markle H.V. Cobalamin. Crit Rev Clin Lab Sci. 1996;33(4):247–356. https://doi.org/10.3109/10408369609081009..
DOI: 10.3109/10408369609081009

Markle H.V. Cobalamin. Crit Rev Clin Lab Sci. 1996;33(4):247–356. https://doi.org/10.3109/10408369609081009..
DOI: 10.3390/molecules14010329

Павлов Ч.С., Дамулин И.В., Шульпекова Ю.О., Андреев Е.А. Неврологические расстройства при дефиците витамина В12. Терарапевтический архив. 2019;91(4):122–129. Режим доступа: https://cyberleninka.ru/article/n/nevrologicheskie-rasstroystva-pridefitsite-vitamina-v12..
DOI: 10.3109/10408369609081009https://cyberleninka.ru/article/n/nevrologicheskie-rasstroystva-pridefitsite-vitamina-v12

Jayabalan B., Low L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55–59. https://doi.org/10.11622/smedj.2016027..
DOI: 10.11622/smedj.2016027https://cyberleninka.ru/article/n/nevrologicheskie-rasstroystva-pri-defitsite-vitamina-v12

Верткин А.Л., Городецкий В.В. В чем преимущество бенфотиаминсодержащих препаратов Мильгамма и Бенфогамма в лечении диабетической полинейропатии. Фарматека. 2006;(11):83–89. Режим доступа: https://pharmateca.ru/ru/archive/article/6589..
DOI: 10.11622/smedj.2016027https://pharmateca.ru/ru/archive/article/6589

Маркина О.А. Значение лекарственной формы и пути введения витаминов группы В для обеспечения эффективного лечения диабетической полиневропатии. Клиническая фармакология и терапия. 2003;(2):6–9. Режим доступа: https://medi.ru/info/11187.https://medi.ru/info/11187

Маркина О.А. Значение лекарственной формы и пути введения витаминов группы В для обеспечения эффективного лечения диабетической полиневропатии. Клиническая фармакология и терапия. 2003;(2):6–9. Режим доступа: https://medi.ru/info/11187.https://pharmateca.ru/ru/archive/article/6589

Парфенов В.А., Головачева В.А., Фадеев В.В., Воловик А.Ю., Головачева А.А. Оптимизация ведения пациентов с диабетической полиневропатией с помощью междисциплинарного подхода. Медицинский совет. 2017;(1S):71–79. https://doi.org/10.21518/2079-701X-2017-0-71-79..
DOI: 10.21518/2079-701X-2017-0-71-79https://medi.ru/info/11187

Манушарова Р.А., Черкезов Д.И. Применение Нейромультивита при диабетической периферической полинейропатии. Медицинский совет. 2011;(1-2):68–71. Режим доступа: https://cyberleninka.ru/article/n/primenenie-neyromultivita-pri-diabeticheskoy-perifericheskoypolineyropatii..
DOI: 10.21518/2079-701X-2017-0-71-79https://cyberleninka.ru/article/n/primenenie-neyromultivita-pri-diabeticheskoy-perifericheskoypolineyropatii

Токмакова А.Ю., Анциферов М.Б. Возможности использования нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет. 2001;4(2):33–35. https://doi.org/10.14341/2072-0351-5660..
DOI: 10.14341/2072-0351-5660https://cyberleninka.ru/article/n/primenenie-neyromultivita-pri-diabeticheskoy-perifericheskoypolineyropatii

Al Sulaiman K., Aljuhani O., Al Dossari M., Alshahrani A., Alharbi A., Algarni R. et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit Care. 2021;25(1):223. https://doi.org/10.1186/s13054-021-03648-9..
DOI: 10.1186/s13054-021-03648-9

Al Sulaiman K., Aljuhani O., Al Dossari M., Alshahrani A., Alharbi A., Algarni R. et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit Care. 2021;25(1):223. https://doi.org/10.1186/s13054-021-03648-9..
DOI: 10.14341/2072-0351-5660

Branco de Oliveira M.V., Irikura S., Lourenço F.H. B., Shinsato M., Irikura T.C. D. B., Irikura R.B. et al. Encephalopathy responsive to thiamine in severe COVID-19 patients. Brain Behav Immun Health. 2021;14:100252. https://doi.org/10.1016/j.bbih.2021.100252..
DOI: 10.1016/j.bbih.2021.100252

Branco de Oliveira M.V., Irikura S., Lourenço F.H. B., Shinsato M., Irikura T.C. D. B., Irikura R.B. et al. Encephalopathy responsive to thiamine in severe COVID-19 patients. Brain Behav Immun Health. 2021;14:100252. https://doi.org/10.1016/j.bbih.2021.100252..
DOI: 10.1186/s13054-021-03648-9

Shakoor H., Feehan J., Mikkelsen K., Al Dhaheri A.S., Ali H.I., Platat C. et al. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021;144:108–111. https://doi.org/10.1016/j.maturitas.2020.08.007..
DOI: 10.1016/j.maturitas.2020.08.007

Shakoor H., Feehan J., Mikkelsen K., Al Dhaheri A.S., Ali H.I., Platat C. et al. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021;144:108–111. https://doi.org/10.1016/j.maturitas.2020.08.007..
DOI: 10.1016/j.bbih.2021.100252

Kumrungsee T., Zhang P., Chartkul M., Yanaka N., Kato N. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications. Front Nutr. 2020;7:562051. https://doi.org/10.3389/fnut.2020.562051..
DOI: 10.3389/fnut.2020.562051

Kumrungsee T., Zhang P., Chartkul M., Yanaka N., Kato N. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications. Front Nutr. 2020;7:562051. https://doi.org/10.3389/fnut.2020.562051..
DOI: 10.1016/j.maturitas.2020.08.007

Lopes M.J. S. Can vitamin B12 be an adjuvant to COVID-19 treatment? GSC Biological and Pharmaceutical Sciences. 2020;11(3):1–5. Available at: https://gsconlinepress.com/journals/gscbps/content/can-vitamin-b12-beadjuvant-covid-19-treatment..
DOI: 10.3389/fnut.2020.562051https://gsconlinepress.com/journals/gscbps/content/can-vitamin-b12-beadjuvant-covid-19-treatment

Менделевич Е.Г. Дефицит витаминов группы В: аспекты диагностики и терапии. РМЖ. 2016;24(7):442–444. Режим доступа: https://rmj.ru/articles/nevrologiya/Deficit_vitaminov_gruppy_V_aspekty_diagnostikii_terapii.https://rmj.ru/articles/nevrologiya/Deficit_vitaminov_gruppy_V_aspekty_diagnostikii_terapii

Менделевич Е.Г. Дефицит витаминов группы В: аспекты диагностики и терапии. РМЖ. 2016;24(7):442–444. Режим доступа: https://rmj.ru/articles/nevrologiya/Deficit_vitaminov_gruppy_V_aspekty_diagnostikii_terapii.https://gsconlinepress.com/journals/gscbps/content/can-vitamin-b12-beadjuvant-covid-19-treatment

Бирюкова Е.В., Ганненкова Е.С., Соловьева И.В. Диабетическая полинейропатия: чего мы достигли в понимании проблемы? РМЖ. 2020;28(1):14–19. Режим доступа: https://rmj.ru/articles/endokrinologiya/Diabeticheskaya_polineyropatiya_chego_my_dostigli_v_ponimanii_problemyhttps://rmj.ru/articles/endokrinologiya/Diabeticheskaya_polineyropatiya_chego_my_dostigli_v_ponimanii_problemy

Бирюкова Е.В., Ганненкова Е.С., Соловьева И.В. Диабетическая полинейропатия: чего мы достигли в понимании проблемы? РМЖ. 2020;28(1):14–19. Режим доступа: https://rmj.ru/articles/endokrinologiya/Diabeticheskaya_polineyropatiya_chego_my_dostigli_v_ponimanii_problemyhttps://rmj.ru/articles/nevrologiya/Deficit_vitaminov_gruppy_V_aspekty_diagnostikii_terapii